Cytogenetic Response in Chronic Myeloid Leukaemia Patients Treated with Imatinib Mesylate Homolog-Drugs: 6 Year’s Transitional StudyReport as inadecuate




Cytogenetic Response in Chronic Myeloid Leukaemia Patients Treated with Imatinib Mesylate Homolog-Drugs: 6 Year’s Transitional Study - Download this document for free, or read online. Document in PDF available to download.

Background: Treatment forChronic Myeloid Leukaemia CML is mainly imatinib mesylate IM fromoriginal-brand, Glivec? orgeneric-type homologs, Imatib?. Materials and Methods: A collectionof 149 CML patients was treated over a period of 6 years at Hiwa hospital.These patients were clustered into three groups: Group A was treated withImatib for more than one year. All survivors of group A patients were switchedto Glivec, classified as group B. Group C received only Glivec after June 2011.Imatib and Glivec are administered at doses 400-, 600- and 800-mg according tothe CML stage. Results: Among group A patients, 68 60% were in completehaematological response CHR, 32 28.3% developed acceleration and 13 11.5%patients were deceased. After switching to Glivec group B, 69 69% patientsremained in CHR, 10 10% patients weredeceased and 21 21% patients remainedin acceleration. Of the 36 patients in group C, 33 91.7% were in CHR, 1 2.8% were inacceleration and 2 5.5% deceased. Those patients with CHR were testedrandomly for BCR-ABL by FISH, and only 1-25 4% patients were found withcomplete cytogenetic response CCyR in group A, while 31-42 73.8% and 13-1776.5% have CCyR in group B and C, respectively. Conclusions: Our resultsdemonstrate a less cytogenetic response to treatment in patients of CML, whoreceived the Imatib therapy, while a significant cytogenetic remission wasfound in patients with CHR after they switched to Glivec.

KEYWORDS

Chronic Myeloid Leukaemia, Glivec®, Imatib®, Complete Haematological Response, Cytogenetic Remission

Cite this paper

Khoshnaw, N. , Francis, B. , Safar, B. , Mahmood, S. and Nore, B. 2014 Cytogenetic Response in Chronic Myeloid Leukaemia Patients Treated with Imatinib Mesylate Homolog-Drugs: 6 Year’s Transitional Study. Journal of Cancer Therapy, 5, 453-459. doi: 10.4236-jct.2014.55052.





Author: Najmaddin Khoshnaw, Bassam Francis, Banaz M. Safar, Salim S. Mahmood, Beston F. Nore

Source: http://www.scirp.org/



DOWNLOAD PDF




Related documents